84 results about "Lymphatic tissues" patented technology

Oral phototherapy applicators are disclosed that are sized and shaped so as to fit at least partially in a user's mouth and have at least one radiation emitting element coupled to an apparatus body to irradiate a portion of the oral cavity with phototherapeutic radiation along multiple directions. In one aspect, the apparatus is configured to direct radiation to at least one portion of the oral cavity, such as the teeth, cheeks, tongue, palate, throat, lymphatic tissue, blood, glands, follicles, collagen, pigmentation or facial tissue, generally. The apparatus can further include bristles to provide a phototherapeutic toothbrush. Alternatively, the apparatus body can be adapted for placement in a fixed position relative to the oral cavity during phototherapy.

Methods and compositions based on the elucidation of the role of Prox1 in lymphatic tissue development in normal and tumor tissue are provided. Included are methods for determining the extent of lymphatic involvement in a tumor, methods for purifying endothelial precursor cells predisposed to develop into lymphatic tissue, and methods for promoting the development of lymphatic tissue. Pharmaceutical compositions and gene therapy vectors useful in the latter methods are provided.

CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 23-25, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 26-28, respectively.

The subject matter of the present disclosure generally relates to techniques for neuromodulation of lymphatic tissue that include applying one or more energy pulses to a neuron of a subject, e.g., via an electrode positioned to deliver sufficient energy to the neuron, to modulate immune function. For example, an adaptive immune reflex of a subject may be modulated via neuromodulation

The present invention encompasses compounds of Formula I:as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1 / Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 17-19, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 20-22, respectively.

The invention discloses chimeric antigen receptor-T cells secreting and expressing IL15RA-IL15 fusion proteins and CCL21 chemotactic factors as well as application thereof. Super IL15 can promote activation and proliferation of T (especially memory T) cells, NK cells and NKT cells; and CCL21 can recruit peripheral CCR7-positive initial T cells, memory T cells and dendritic cells (DC) into lymphoidtissue or tumor lesions so as to activate active anti-tumor immune response (such as cancer memory T cells) in the body, thereby significantly improving efficiency and remission rate, as well as reducing recurrence rate after remission.

The present invention relates to compositions and methods of inhibiting stem cell binding to organs and tissues, including the blocking of stem cell binding to germinal centers present in lymph tissue. Disclosed are compositions and methods for regenerating germinal centers in lymphatic tissue. Included in the compositions are adjuvants, agonists to CD40, CD28 and the IL-21 receptor, and antagonist to CD20.

The invention relates to contrast agents for medical science, in particular to a lymph targeted nuclear magnetic resonance imaging contrast agent with brown algal polysaccharide serving as a carrier and a preparation method and application of the lymph targeted nuclear magnetic resonance imaging contrast agent with the brown algal polysaccharide serving as the carrier. The macromolecular contrast agent high in water solubility is prepared by taking the brown algal polysaccharide as the carrier, taking mannose or mannose derivatives as a mannose receptor MBP (mannose binding protein) recognition group and taking paramagnetic metal ion chelates as a nuclear magnetic resonance imaging group. Lymph tissue binding force is increased, and combination of the mannose or mannose derivative group introduced into the synthetic contrast agent with mannose receptors enriched in lymph tissues is realized. In addition, after hypodermic injection of the contrast agent, lymph vessels and lymph glands are clearly developed under scanning of a nuclear magnetic resonance equipment, lymph gland signal enhancement rate of one side, with the contrast agent injected, of an animal body is remarkably increased while enhancement time is remarkably prolonged, distinct drawing and precise positioning of the lymph glands and the lymph vessels are realized, and a great significance to examination and diagnosis of lymphatic diseases is achieved.

The invention discloses a method for detecting short-chain fatty acids in serum and lymphatic tissues based on GC-MS. The method comprises the following steps: pretreating lymphatic tissues to obtaina lymphatic extracting solution; adding an internal standard substance into the serum or lymph extracting solution, and adding benzyl pentafluorobromide for derivatization reaction; and extracting thederived solution, and detecting acetic acid, propionic acid and butyric acid in the extract by using GC-MS. A gas chromatography-mass spectrometry rapid determination method for detecting three short-chain fatty acids in the serum and lymphatic tissues is established through a derivatization method. Different biological samples are pretreated and subjected to derivatization treatment, the internal standard is added for correction and accurate quantification is achieved.

The invention discloses a device for fetching meat from poultry. The device comprises side frames, wherein two groups of the side frames are symmetrically provided, the side frames are respectively and movably connected with cutting moving rods and dewatering moving rods, both ends of an operating floor are correspondingly provided with a rotating motor, a clamping electric push rod is fixedly connected with a plurality of clamping triangular heads. The invention also discloses a technology for fetching meat from poultry by the device. The technology comprises steps as follows: S1 placing poultry; S2 cutting the necks of poultry; S3 performing clamping and rotating; S4 removing the skin of the necks; and S5 performing rotating and dewatering. Through taking the combination of the operatingfloor and a cutting knife, carrying out operation of removing the skin by the way of separation and rotation of the neck and the skin of the neck, and a plurality of the dewatering rods in conjunction with each other, the technology can strike off the lymphatic tissues attaching on the neck, and the technology is good in effect and worth promoting.

Aspects of the invention include methods for visualizing lymphatic tissue in an ocular region, e.g., the cornea, of a living subject, such as a mouse or human. In certain embodiments, the methods include contacting the region with a fluorescently-labeled lymphatic tissue-specific dye, e.g., FITC or rhodamine labeled dextran, and detecting the labeled dye to visualize lymphatic tissue in the region, where the visualization may vary, from an image obtained at a single time to a video over a period of time. The invention finds use in a variety of different applications, including research and therapeutic applications.